]> 2026-04-12T02:22:10-07:00 Fotemustine 0 en While specific common side effects were not detailed, nitrosoureas typically present with myelosuppression, nausea, and potential for liver enzyme elevation. The toxicity profile necessitates careful monitoring and management, similar to other agents in its class. 2025-01-18T08:26:32Z 2460693.8517593 Fotemustine 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has Usefulness Explanation","Fotemustine has shown promising results in patients with recurrent GBM, especially when administered every two weeks for five consecutive treatments at a dose of 80 mg\/sq.-meter followed by maintenance therapy every four weeks. This regimen resulted in a PFS-6 value of 61% and a median time to progression of 6.7 months, indicating potential as an effective treatment option in this setting."] Fotemustine# ERR0de0b09fdf871942cb9b8a10a8978dce 0 [2,"smw-datavalue-wikipage-property-invalid-title","Has original text","Fotemustine represents a newer addition to the nitrosourea family of chemotherapeutics, showing efficacy in treating recurrent GBM post-Stupp protocol. Its unique dosing schedule, which has yielded higher PFS-6 values, suggests fotemustine as a viable option for patients who have failed initial treatments. Continued research and direct comparisons, such as those conducted in Italian studies, further support its role in the treatment landscape for GBM, albeit with a need for careful consideration of toxicity management."] Fotemustine# ERRa3f62c6665776505f0db7c26c19aebf1 Has treatment name 102 en Has treatment name